-DOCSTART- -X- O
In -X- _ O
an -X- _ O
effort -X- _ O
to -X- _ O
circumvent -X- _ O
resistance -X- _ O
to -X- _ O
rapamycin -X- _ O
– -X- _ O
an -X- _ O
mTOR -X- _ O
inhibitor -X- _ O
- -X- _ O
we -X- _ O
searched -X- _ O
for -X- _ O
novel -X- _ O
rapamycin-downstream-targets -X- _ O
that -X- _ O
may -X- _ O
be -X- _ O
key -X- _ O
players -X- _ O
in -X- _ O
the -X- _ O
response -X- _ O
of -X- _ O
cancer -X- _ O
cells -X- _ O
to -X- _ O
therapy. -X- _ O
We -X- _ O
found -X- _ O
that -X- _ O
rapamycin -X- _ B-Intervention
, -X- _ O
at -X- _ O
nM -X- _ O
concentrations -X- _ O
, -X- _ O
increased -X- _ B-Outcome
phosphorylation -X- _ I-Outcome
of -X- _ I-Outcome
eukaryotic -X- _ I-Outcome
initiation -X- _ I-Outcome
factor -X- _ I-Outcome
( -X- _ I-Outcome
eIF -X- _ I-Outcome
) -X- _ I-Outcome
2α -X- _ I-Outcome
in -X- _ I-Outcome
rapamycin-sensitive -X- _ I-Outcome
and -X- _ I-Outcome
estrogen-dependent -X- _ I-Outcome
MCF-7 -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
had -X- _ I-Outcome
only -X- _ I-Outcome
a -X- _ I-Outcome
minimal -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
eIF2α -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
rapamycin-insensitive -X- _ I-Outcome
triple-negative -X- _ I-Outcome
MDA- -X- _ I-Outcome
MB-231 -X- _ I-Outcome
cells. -X- _ I-Outcome
Addition -X- _ O
of -X- _ O
salubrinal -X- _ B-Intervention
– -X- _ O
an -X- _ O
inhibitor -X- _ B-Intervention
of -X- _ I-Intervention
eIF2α -X- _ I-Intervention
dephosphorylation -X- _ I-Intervention
– -X- _ O
decreased -X- _ B-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
surface -X- _ I-Outcome
marker -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
capacity -X- _ I-Outcome
for -X- _ I-Outcome
self -X- _ I-Outcome
renewal -X- _ I-Outcome
, -X- _ I-Outcome
increased -X- _ I-Outcome
senescence -X- _ I-Outcome
and -X- _ I-Outcome
induced -X- _ I-Outcome
clonogenic -X- _ I-Outcome
cell -X- _ I-Outcome
death -X- _ I-Outcome
, -X- _ I-Outcome
suggesting -X- _ I-Outcome
that -X- _ I-Outcome
excessive -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
of -X- _ I-Outcome
eIF2α -X- _ I-Outcome
is -X- _ I-Outcome
detrimental -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
cells -X- _ I-Outcome
' -X- _ I-Outcome
survival. -X- _ I-Outcome
Treating -X- _ O
cells -X- _ O
with -X- _ O
salubrinal -X- _ O
enhanced -X- _ O
radiation-induced -X- _ B-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
eIF2α -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
and -X- _ I-Outcome
clonogenic -X- _ I-Outcome
death -X- _ I-Outcome
and -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
irradiated -X- _ I-Outcome
cells -X- _ I-Outcome
are -X- _ I-Outcome
more -X- _ I-Outcome
sensitive -X- _ I-Outcome
to -X- _ I-Outcome
increased -X- _ I-Outcome
eIF2α -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
than -X- _ I-Outcome
non-irradiated -X- _ I-Outcome
ones. -X- _ I-Outcome
Similar -X- _ O
to -X- _ O
salubrinal -X- _ O
- -X- _ O
the -X- _ O
phosphomimetic -X- _ B-Intervention
eIF2α -X- _ I-Intervention
variant -X- _ I-Intervention
- -X- _ I-Intervention
S51D -X- _ I-Intervention
- -X- _ O
increased -X- _ B-Outcome
sensitivity -X- _ I-Outcome
to -X- _ I-Outcome
radiation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
both -X- _ I-Outcome
abrogated -X- _ I-Outcome
radiation-induced -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
breast -X- _ I-Outcome
cancer -X- _ I-Outcome
type -X- _ I-Outcome
1 -X- _ I-Outcome
susceptibility -X- _ I-Outcome
gene -X- _ I-Outcome
, -X- _ I-Outcome
thus -X- _ I-Outcome
implicating -X- _ I-Outcome
enhanced -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
of -X- _ I-Outcome
eIF2α -X- _ I-Outcome
in -X- _ I-Outcome
modulation -X- _ I-Outcome
of -X- _ I-Outcome
DNA -X- _ I-Outcome
repair. -X- _ I-Outcome
Indeed -X- _ O
, -X- _ O
salubrinal -X- _ O
inhibited -X- _ B-Outcome
non- -X- _ I-Outcome
homologous -X- _ I-Outcome
end -X- _ I-Outcome
joining -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
homologous -X- _ I-Outcome
recombination -X- _ I-Outcome
repair -X- _ I-Outcome
of -X- _ I-Outcome
double -X- _ I-Outcome
strand -X- _ I-Outcome
breaks -X- _ I-Outcome
that -X- _ I-Outcome
were -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
I-SceI -X- _ I-Outcome
in -X- _ I-Outcome
green -X- _ I-Outcome
fluorescent -X- _ I-Outcome
protein -X- _ I-Outcome
reporter -X- _ I-Outcome
plasmids. -X- _ I-Outcome
In -X- _ O
addition -X- _ O
to -X- _ O
its -X- _ O
effect -X- _ O
on -X- _ O
radiation -X- _ O
, -X- _ O
salubrinal -X- _ B-Outcome
enhanced -X- _ I-Outcome
eIF2α -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
and -X- _ I-Outcome
clonogenic -X- _ I-Outcome
death -X- _ I-Outcome
in -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
histone -X- _ I-Outcome
deacetylase -X- _ I-Outcome
inhibitor -X- _ I-Outcome
– -X- _ I-Outcome
vorinostat. -X- _ I-Outcome
Finally -X- _ O
, -X- _ O
the -X- _ O
catalytic -X- _ O
competitive -X- _ O
inhibitor -X- _ O
of -X- _ O
mTOR -X- _ O
- -X- _ O
Ku-0063794 -X- _ B-Intervention
- -X- _ O
increased -X- _ B-Outcome
phosphorylation -X- _ I-Outcome
of -X- _ I-Outcome
eIF2α -X- _ I-Outcome
demonstrating -X- _ I-Outcome
further -X- _ I-Outcome
the -X- _ I-Outcome
involvement -X- _ I-Outcome
of -X- _ I-Outcome
mTOR -X- _ I-Outcome
activity -X- _ I-Outcome
in -X- _ I-Outcome
modulating -X- _ I-Outcome
eIF2α -X- _ I-Outcome
phosphorylation. -X- _ I-Outcome
These -X- _ O
experiments -X- _ O
suggest -X- _ O
that -X- _ O
excessive -X- _ B-Outcome
phosphorylation -X- _ I-Outcome
of -X- _ I-Outcome
eIF2α -X- _ I-Outcome
decreases -X- _ I-Outcome
survival -X- _ I-Outcome
of -X- _ I-Outcome
cancer -X- _ I-Outcome
cells -X- _ I-Outcome
; -X- _ O
making -X- _ O
eIF2α -X- _ O
a -X- _ O
worthy -X- _ O
target -X- _ O
for -X- _ O
drug -X- _ O
development -X- _ O
, -X- _ O
with -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
enhance -X- _ O
the -X- _ O
cytotoxic -X- _ O
effects -X- _ O
of -X- _ O
established -X- _ O
anti- -X- _ O
neoplastic -X- _ O
therapies -X- _ O
and -X- _ O
circumvent -X- _ O
resistance -X- _ O
to -X- _ O
rapalogues -X- _ O
and -X- _ O
possibly -X- _ O
to -X- _ O
other -X- _ O
drugs -X- _ O
that -X- _ O
inhibit -X- _ O
upstream -X- _ O
components -X- _ O
of -X- _ O
the -X- _ O
mTOR -X- _ O
pathway -X- _ O
. -X- _ O

